Objective: We sought to demonstrate that the combination of a local vasodilator (verapamil), modern materials, patent hemostasis, and intravenous anticoagulant only in the case of percutaneous coronary intervention, as compared to default heparin administration after sheath insertion, may optimize a combined endpoint, including radial artery oc-clusion (RAO), radial artery spasm (RAS), and access site complication. Methods: This is a prospective, single-center, double-blind randomized trial. Overall, 418 patients undergoing a transradial approach (TRA) for coronary procedures were randomized 1: 1 to receive intraradial verapamil (5 mg) or heparin (5,000 IU) after a 6-Fr sheath insertion. The primary outcome was the 24-h occurrence of RAO (ultrasound confirmation), access site complication, and RAS requiring the bailout administration of vasodilators. Results: The combined primary outcome occurred in 127 (30%) patients. It was significantly lower in patients randomized to verapamil as compared to others (26 vs. 35%, p = 0.03). This was mainly due to a significant reduction in RAS (3 vs. 10%, p = 0.006). The 24-h and 30-day occurrence of RAO did not differ between the study groups. Conclusion: Local administration of verapamil versus heparin reduces RAS, without increasing RAO, which appears to be strictly related to radial artery diameter and hemostasis time.

Keywords:
Radial artery, Spasm, Occlusion
1.
Rashid M, Kwok CS, Pancholy S, Chugh S, Kedev SA, Bernat I, Ratib K, Large A, Fraser D, Nolan J, Mamas MA: Radial artery occlusion after transradial interventions: a systematic review and meta-analysis. J Am Heart Assoc 2016; 5:e002686.
2.
Cooper CJ, El-Shiekh RA, Cohen DJ, Blaesing L, Burket MW, Basu A, Moore JA: Effect of transradial access on quality of life and cost of cardiac catheterization: a randomized comparison. Am Heart J 1999; 138: 430–436.
3.
Mitchell MD, Hong JA, Lee BY, Umscheid CA, Bartsch SM, Don CW: Systematic review and cost-benefit analysis of radial artery access for coronary angiography and intervention. Circ Cardiovasc Qual Outcomes 2012; 5: 454–462.
4.
Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, et al: Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet 2015; 385: 2465–2476.
5.
Spaulding C, Lefèvre T, Funck F, Thébault B, Chauveau M, Ben Hamda K, Chalet Y, Monségu H, Tsocanakis O, Py A, Guillard N, Weber S: Left radial approach for coronary angiography: results of a prospective study. Cathet Cardiovasc Diagn 1996; 39: 365–370.
6.
Kiemeneij F, Yoshimachi F, Matsukage T, Amoroso G, Fraser D, Claessen BE, Saito S: Focus on maximal miniaturisation of transradial coronary access materials and techniques by the Slender Club Japan and Europe: an overview and classification. EuroIntervention 2015; 10: 1178–1186.
7.
Boyer N, Beyer A, Gupta V, Dehghani H, Hindnavis V, Shunk K, Zimmet J, Yeghiazarians Y, Ports T, Boyle A: The effects of intra-arterial vasodilators on radial artery size and spasm: implications for contemporary use of trans-radial access for coronary angiography and percutaneous coronary intervention. Cardiovasc Revasc Med 2013; 14: 321–324.
8.
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A: 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2014; 35: 2541–2619.
9.
Campo G, Menozzi M, Guastaroba P, Vignali L, Belotti LM, Casella G, Berti E, Solinas E, Guiducci V, Biscaglia S, Pavasini R, De Palma R, Manari A: Same-day transfer for the invasive strategy of patients with non-ST-segment elevation acute coronary syndrome admitted to spoke hospitals: data from the Emilia-Romagna Regional Network. Eur Heart J Acute Cardiovasc Care 2016; 5: 428–434.
10.
Valgimigli M, Campo G, Penzo C, Tebaldi M, Biscaglia S, Ferrari R: Transradial coronary catheterization and intervention across the whole spectrum of Allen test results. J Am Coll Cardiol 2014; 63: 1833–1841.
11.
Tumscitz C, Pirani L, Tebaldi M, Campo G, Biscaglia S: Seven French radial artery access for PCI: a prospective single-center experience. Int J Cardiol 2014; 176: 1074–1075.
12.
Benit E, Vranckx P, Jaspers L, Jackmaert R, Poelmans C, Coninx R: Frequency of a positive modified Allen’s test in 1,000 consecutive patients undergoing cardiac catheterization. Cathet Cardiovasc Diagn 1996; 38: 352–354.
13.
Barbeau GR, Arsenault F, Dugas L, Simard S, Larivière MM: Evaluation of the ulnopalmar arterial arches with pulse oximetry and ple-thysmography: comparison with the Allen’s test in 1,010 patients. Am Heart J 2004; 147: 489–493.
14.
Pancholy S, Coppola J, Patel T, Roke-Thomas M: Prevention of radial artery occlusion-patent hemostasis evaluation trial (PROPHET study): a randomized comparison of traditional versus patency documented hemostasis after transradial catheterization. Catheter Cardiovasc Interv 2008; 72: 335–340.
15.
Bertrand OF: Acute forearm muscle swelling post transradial catheterization and compartment syndrome: prevention is better than treatment! Catheter Cardiovasc Interv 2010; 75: 366–368.
16.
Garg N, Madan BK, Khanna R, Sinha A, Kapoor A, Tewari S, Kumar S, Goel PK: Incidence and predictors of radial artery occlusion after transradial coronary angioplasty: Doppler-guided follow-up study. J Invasive Cardiol 2015; 27: 106–112.
17.
Dharma S, Kedev S, Patel T, Kiemeneij F, Gilchrist IC: A novel approach to reduce radial artery occlusion after transradial catheterization: postprocedural/prehemostasis intra-arterial nitroglycerin. Catheter Cardiovasc Interv 2015; 85: 818–825.
18.
Pancholy SB, Bernat I, Bertrand OF, Patel TM: Prevention of radial artery occlusion after transradial catheterization: the PROPHET-II randomized trial. JACC Cardiovasc Interv 2016; 9: 1992–1999.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.